Compare Toyota Motor Corp (TM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs Viatris Inc — how do they compare? Toyota Motor Corp trades at $180.15 (market cap $212.22B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Toyota Motor Corp is far larger — about 10.7× Viatris Inc's market cap, and Toyota Motor Corp pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| TM | VTRS | |
|---|---|---|
Market Cap | $212.22B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $248.29 | $17.39 |
52-Week Low | $166.50 | $8.74 |
Enterprise Value | $376.42B | $32.00B |
Dividend Yield | 3.51% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor (TM) trades at $180.34, up 1.54% today, showing strong fundamental metrics with a P/E of 9.78 and consistent earnings beats. Technical indicators are neutral overall, with the stock near resistance at $182. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment.
The outlook is positive given undervaluation signals and hybrid vehicle leadership, but risks include margin pressure from rising costs and competitive auto market dynamics. Analyst consensus is mixed with 37.5% buy ratings, suggesting cautious optimism amid macroeconomic uncertainties.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
